A phase 1, multicenter, open‐label study to evaluate the pharmacokinetics, safety, and tolerability of a single dose of rimegepant in children (aged ≥6 to <12 years) with a history of migraine

Documenti analoghi

• Safety, tolerability, and pharmacokinetics of single and multiple ascending doses of zavegepant nasal spray in healthy adults from two phase 1 randomized, placebo‐controlled trials
  di: Richard Bertz, et al.
  Pubblicazione: (2025)
• Effects of multiple‐dose administration of zavegepant nasal spray on the single‐dose pharmacokinetics of ethinyl estradiol‐levonorgestrel
  di: Rajinder Bhardwaj, et al.
  Pubblicazione: (2024)
• Assessment of pharmacokinetic and pharmacodynamic interactions between zavegepant and sumatriptan: A phase 1, randomized, placebo‐controlled study in healthy adults
  di: Rajinder Bhardwaj, et al.
  Pubblicazione: (2024)
• Comparative bioavailability of single‐dose zavegepant during and between migraine attacks: A phase 1, randomized, open‐label, fixed‐sequence, two‐period study
  di: Richard J. Bertz, et al.
  Pubblicazione: (2024)
• A 52‐week open‐label extension study to evaluate the safety and efficacy of oral rimegepant for the preventive treatment of migraine
  di: David Kudrow, et al.
  Pubblicazione: (2025)